Dietary Supplements

Comments on the U.S. government’s position concerning draft vitamin and mineral supplement guidelines before the Codex Committee on Nutrition and Foods for Special Dietary Uses.

CHPA supports rules governing the regulation of dietary supplements as a special type of food. The association has long advocated Good Manufacturing Practices for dietary supplements.

CHPA seeks clarification concerning FDA’s interpretation of the recordkeeping requirement as applied to packaging manufacturers and distributors.

CHPA and CRN support FDA efforts to institute a Task Force on Consumer Health Information for Better Nutrition.

CHPA is supportive of the FDA’s proposed regulation to implement Section 307 of the Public Health Security and Bioterrorism Preparedness and Response Act. However, CHPA encourages FDA to make the implementation of the Act less burdensome on industry while ensuring the safeguards that Congress sought to construct for the American public.

CHPA is supportive of the FDA’s proposed regulation to implement Section 305 of the Bioterrorism Act. However, CHPA encourages FDA to reconsider its position with respect to the definition of food and the confidentiality afforded to the information provided to the agency.

CHPA endorses PhRMA’s analysis and conclusions concerning the First Amendment protections for trade names. These legal principles apply equally to the selection and use of trade names for OTC medicine and dietary supplement products.

CHPA charged IOM to develop a proposed framework for categorizing and prioritizing DS ingredients based on safety issues, describe a process for developing a system of scientific reviews for evaluating the safety of DS ingredients, and develop at least six scientific reviews as prototypes for the system.

Comments before the White House Commission on Complementary and Alternative Medicine Policy on information development and dissemination.

CHPA submits these written comments in response to FDA’s notice in the Federal Register concerning “Guidance for Industry: Significant Scientific Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplements.”